StockVS

NovaBay Pharmaceuticals Inc (NBY) Stock Analysis

Healthcare

NovaBay Pharmaceuticals Inc

$1.31

$-0.10 (-7.09%)

Last Updated: May 26, 2026

Price History

Analysis

Company Overview

NovaBay Pharmaceuticals, Inc. operates primarily as an accumulator and holder of digital assets, specifically focusing on the deployment of SKY, a protocol token integral to the decentralized Sky Protocol ecosystem. The company is classified within the Healthcare sector, yet its specific operational industry is Biotechnology, creating a unique positioning where the entity leverages blockchain-based networks rather than traditional pharmaceutical development pipelines. This biotechnology classification suggests a strategic alignment with the broader healthcare innovation landscape, although the actual business activities center on digital asset accumulation and network participation. The firm currently employs two individuals and maintains a total market capitalization of $39.94 million, while its reported annual revenue is listed as N/A. The absence of reported revenue combined with a market cap of $39.94 million indicates that the company is a micro-cap entity deriving its valuation primarily from potential future utility of its digital assets rather than current cash generation from sales. The minimal employee count of two reflects a lean operational structure typical of early-stage digital asset holding companies that rely on infrastructure partnerships rather than large internal teams.

Financial Health

The company reports a Net Income (TTM) of $-33,222,000 and an EBITDA of $-7,578,333, while the Revenue (TTM) figure is unavailable. The significant gap between the unavailable revenue and the substantial net loss of $-33,222,000 reveals a cost structure where operating expenses and asset depreciation heavily outweigh any potential income from token holdings or protocol fees. Free Cash Flow stands at $-4,935,750, indicating that the company is consuming cash reserves to fund its operations and digital asset accumulation strategies rather than generating liquidity from core activities. Gross Margin is recorded at 0.0%, which typically suggests that the cost of goods sold equals the revenue, a scenario common for holding entities where the primary cost is the purchase price of the digital assets themselves. Operating Margin presents an anomalous figure of 350.1%, which mathematically occurs when operating expenses are negative relative to revenue or when revenue is zero, implying that the company's non-operating income or asset write-downs are driving this specific metric. Profit Margin is 0.0%, confirming that the company is not generating net profit from its current operations. On the balance sheet, NovaBay holds $7.96 million in cash against $776,000 in debt, creating a highly conservative leverage position despite the negative debt-to-equity ratio which is listed as N/A due to the lack of positive equity. The Current Ratio is 7.60, a figure that indicates robust short-term liquidity and a strong ability to cover current liabilities with its available cash and digital asset equivalents. Return on Equity is N/A because there is no positive equity base, while Return on Assets is -76.1%, which reveals that management is currently utilizing the company's asset base to generate significant losses rather than positive returns.

Valuation Assessment

The P/E Ratio (TTM) is listed as N/A due to the absence of positive earnings, while the Forward P/E is -1.83, a negative multiple that reflects the expectation of continued losses rather than a standard earnings trajectory. The Price to Book ratio is -1.63, indicating that the market values the company at a negative multiple of its book value, which suggests significant liabilities or goodwill impairments relative to the stock price. The Price to Sales ratio is N/A because revenue data is unavailable, and the EV/EBITDA stands at -4.37, suggesting that the enterprise value is negative relative to earnings before interest, taxes, depreciation, and amortization. The 52-week high is $99.75 and the 52-week low is $1.11, defining a massive trading range where the current valuation sits far below the historical peak. The beta value is 0.20, which indicates that the stock price is significantly less volatile than the broader market, moving with a low correlation to general market fluctuations. These valuation metrics collectively paint a picture of a high-risk, speculative asset where traditional valuation models like P/E are inapplicable due to the loss-making status of the enterprise.

Growth & Income

Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning there is insufficient historical data to calculate year-over-year expansion rates for this specific reporting period. Because the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, which implies that all available earnings, if any, or the company's cash reserves are being reinvested into the accumulation of digital assets rather than distributed to shareholders. The lack of a dividend payout aligns with the business model of holding digital assets for long-term appreciation or protocol support rather than providing immediate income to investors. The overall growth and income profile is characterized by a reliance on digital asset accumulation rather than traditional revenue expansion or dividend income generation.

Peer Comparison

NovaBay Pharmaceuticals Inc (NBY) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NovaBay Pharmaceuticals Inc NBY $51.92M N/A
Vertex Pharmaceuticals Incorporated VRTX $110.64B 25.8
Regeneron Pharmaceuticals, Inc. REGN $66.98B 15.6
argenx SE ARGX $50.52B 36.0

The Biotechnology industry average P/E ratio is 53.8x. NovaBay Pharmaceuticals Inc trades at a P/E of N/A.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About NovaBay Pharmaceuticals Inc

NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Visit website →

Key Statistics

Market Cap
$51.92M
P/E Ratio
N/A
52-Week High
$99.75
52-Week Low
$1.11
Avg Volume
462.47K
Beta
0.16

Data provided by Yahoo Finance via yfinance. Updated daily.

Company Info

Exchange
AMEX
Country
United States
Employees
2